Our Protac Technology

Targeted protein degradation for the treatment of cancers and a wide range of other diseases

Our proprietary Proteolysis-Targeting Chimera, or PROTACTM protein degraders, work by inducing the cell’s ubiquitin-proteasome system to find, degrade and remove disease-causing proteins. We believe our technology has the potential to deliver a safer, more robust targeted response than conventional small molecule inhibitors, and may address the 80% of proteins that are currently undruggable.

Learn More

Engaging the Body's Ubiquitin-Proteasome System to Degrade Disease-Causing Proteins

PROTAC Mechanism

The PROTAC works by recruiting an E3 ligase to tag the target protein for ubiquitination & degradation via the proteasome. After the protein is destroyed, the PROTAC continues its mission.

Our Therapeutic Programs

We are initially focused on developing first-in-class PROTACs for well-validated targets in oncology. Our wholly owned pipeline also includes next generation protein targets that are undruggable by traditional approaches to protein inhibition.


Academic Collaborations